Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX1901 tablets in moderate-to-severe plaque psoriasis (Phase III, randomized, double-blind, placebo-controlled)
CTR20251872Phase 3Active
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing SYHX1901 active arm with Placebo arm (2 arms). Primary endpoints: Proportion of subjects achieving PASI 75 at week 16 and Proportion of subjects achieving sPGA 0 or 1 at week 16. Started Jun 2025; status: active.
02
Drugs
SYHX-1901
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20251872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251872.